Cargando…
Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study
Background and aims: Due to its involvement in tumor biology as well as tumor-associated stroma cell responses, recent data suggested a potential role of miR-29 as a biomarker for different malignancies. However, its role in neuroendocrine tumors (NETs) is only poorly understood. Methods: We measure...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565987/ https://www.ncbi.nlm.nih.gov/pubmed/32899973 http://dx.doi.org/10.3390/jcm9092881 |
_version_ | 1783596054222995456 |
---|---|
author | Özdirik, Burcin Stueven, Anna K. Mohr, Raphael Geisler, Lukas Wree, Alexander Knorr, Jana Demir, Münevver Vucur, Mihael Loosen, Sven H. Benz, Fabian Reiss, Markus Wiedenmann, Bertram Tacke, Frank Jann, Henning Hellberg, Teresa Roderburg, Christoph |
author_facet | Özdirik, Burcin Stueven, Anna K. Mohr, Raphael Geisler, Lukas Wree, Alexander Knorr, Jana Demir, Münevver Vucur, Mihael Loosen, Sven H. Benz, Fabian Reiss, Markus Wiedenmann, Bertram Tacke, Frank Jann, Henning Hellberg, Teresa Roderburg, Christoph |
author_sort | Özdirik, Burcin |
collection | PubMed |
description | Background and aims: Due to its involvement in tumor biology as well as tumor-associated stroma cell responses, recent data suggested a potential role of miR-29 as a biomarker for different malignancies. However, its role in neuroendocrine tumors (NETs) is only poorly understood. Methods: We measured circulating levels of miR-29b in 45 patients with NET and compared them to 19 healthy controls. Results were correlated with clinical records. Results: In our cohort of NET patients treated between 2010 and 2019 at our department, miR-29b serum levels were significantly downregulated when compared to healthy control samples. Further, a significant correlation between chromogranin A (CgA) and relative miR-29b levels was noted. However, serum levels of miR-29b were independent of tumor-related factors such as proliferation activity according to Ki-67 index, tumor grading, the TMN stage of malignant tumors, somatostatin receptor expression or clinical features such as functional or non-functional disease and presence of tumor relapse. Finally, in contrast to previous results from other malignancies, miR-29b serum levels were not a significant predictor of overall survival in NET patients. Conclusion: Our data suggest a role for miR-29b serum levels as a previously unrecognized biomarker for diagnosis of NET. However, miR-29 does not allow for predicting tumor stage or patients’ outcome. |
format | Online Article Text |
id | pubmed-7565987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75659872020-10-26 Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study Özdirik, Burcin Stueven, Anna K. Mohr, Raphael Geisler, Lukas Wree, Alexander Knorr, Jana Demir, Münevver Vucur, Mihael Loosen, Sven H. Benz, Fabian Reiss, Markus Wiedenmann, Bertram Tacke, Frank Jann, Henning Hellberg, Teresa Roderburg, Christoph J Clin Med Article Background and aims: Due to its involvement in tumor biology as well as tumor-associated stroma cell responses, recent data suggested a potential role of miR-29 as a biomarker for different malignancies. However, its role in neuroendocrine tumors (NETs) is only poorly understood. Methods: We measured circulating levels of miR-29b in 45 patients with NET and compared them to 19 healthy controls. Results were correlated with clinical records. Results: In our cohort of NET patients treated between 2010 and 2019 at our department, miR-29b serum levels were significantly downregulated when compared to healthy control samples. Further, a significant correlation between chromogranin A (CgA) and relative miR-29b levels was noted. However, serum levels of miR-29b were independent of tumor-related factors such as proliferation activity according to Ki-67 index, tumor grading, the TMN stage of malignant tumors, somatostatin receptor expression or clinical features such as functional or non-functional disease and presence of tumor relapse. Finally, in contrast to previous results from other malignancies, miR-29b serum levels were not a significant predictor of overall survival in NET patients. Conclusion: Our data suggest a role for miR-29b serum levels as a previously unrecognized biomarker for diagnosis of NET. However, miR-29 does not allow for predicting tumor stage or patients’ outcome. MDPI 2020-09-06 /pmc/articles/PMC7565987/ /pubmed/32899973 http://dx.doi.org/10.3390/jcm9092881 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Özdirik, Burcin Stueven, Anna K. Mohr, Raphael Geisler, Lukas Wree, Alexander Knorr, Jana Demir, Münevver Vucur, Mihael Loosen, Sven H. Benz, Fabian Reiss, Markus Wiedenmann, Bertram Tacke, Frank Jann, Henning Hellberg, Teresa Roderburg, Christoph Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study |
title | Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study |
title_full | Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study |
title_fullStr | Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study |
title_full_unstemmed | Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study |
title_short | Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study |
title_sort | analysis of mir-29 serum levels in patients with neuroendocrine tumors—results from an exploratory study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565987/ https://www.ncbi.nlm.nih.gov/pubmed/32899973 http://dx.doi.org/10.3390/jcm9092881 |
work_keys_str_mv | AT ozdirikburcin analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT stuevenannak analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT mohrraphael analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT geislerlukas analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT wreealexander analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT knorrjana analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT demirmunevver analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT vucurmihael analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT loosensvenh analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT benzfabian analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT reissmarkus analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT wiedenmannbertram analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT tackefrank analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT jannhenning analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT hellbergteresa analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy AT roderburgchristoph analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy |